Synergistic Immunosuppression by PAHs and Arsenite
PAH 和亚砷酸盐的协同免疫抑制
基本信息
- 批准号:8618005
- 负责人:
- 金额:$ 40.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-17 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:Aromatic Polycyclic HydrocarbonsArsenicArsenitesBangladeshBiological MarkersBloodBlood specimenCD28 geneCD3 AntigensCacodylic AcidCancerousCell physiologyCellsCessation of lifeChemicalsChicagoClinicCollaborationsDNA AdductsDNA RepairDataData CollectionDetectionDiseaseEnzyme-Linked Immunosorbent AssayEpidemicEpidemiologistEstersExhalationExposure toFlow CytometryFluorescenceFoodFrequenciesGrantHealthHigh Pressure Liquid ChromatographyHumanImmunologicsImmunologyImmunosuppressionIn VitroIndividualInfectionInflammatoryJointsKnowledgeLaboratoriesLeadLungLung InflammationLung diseasesLymphoidMeasuresMedical RecordsMolecularMononuclearMusNatural Killer CellsNitric OxideOxidative StressParentsParticipantPatient Self-ReportPeripheral Blood Mononuclear CellPhenotypePopulationPrincipal InvestigatorProductionPublic HealthPulmonary Function Test/Forced Expiratory Volume 1Research PersonnelResearch Project GrantsRespiratory Tract InfectionsRespiratory physiologyRiskSamplingSmokerSmokingSmoking StatusStudy SubjectSuperfundT cell differentiationT-Cell ActivationT-Cell ProliferationT-LymphocyteT-Lymphocyte SubsetsTestingTimeTobacco smokeUniversitiesUrineWaterWorkadductairway inflammationbody systemcarboxyfluoresceincigarette smokingcigarette smokingcohortcytokinedesigndrinking waterexposed human populationimmune functionin vivointerestmalemen&aposs groupmonocytemonomethylarsonic acidnon-smokeroxaliplatinperipheral bloodprogramspublic health relevancepulmonary functionsample collectionurinary
项目摘要
This ViCTER application supplements an RO1 from the PI that seeks to understand the mechanisms of
immunosuppression produced by polycyclic aromatic hydrocarbons (PAHs) and arsenic alone and in
combination following exposure of mice and humans. The underlying RO1 grant tests the hypothesis that
arsenic produces synergistic immunosuppression with PAHs which are contained in tobacco smoke by
inhibiting DNA repair of PAH bulky adducts. The PI's lab has demonstrated synergistic immunosuppression by
PAHs and arsenic in vivo in mice and in vitro in human peripheral blood mononuclear cells (HPBMC). This
ViCTER grant supports three highly interactive projects which significantly expand the original aims of the
parent RO1 grant. All three projects rely upon the HEALS cohort in Bangladesh that has been studied by
Columbia University and the University of Chicago with regard to drinking water arsenic exposures. The
present study has been designed by our collaborator Dr. Factor-Litvak (Columbia Univ Superfund Program),
the key epidemiologist for the HEALS study, to examine 200 study subjects in a 2x2 design of 50 per group of
male smokers and nonsmokers who are also exposed to low or high arsenic in water. In Aim 1, Dr. Burchiel's
lab will examine HPBMC obtained from these groups with known arsenic and PAH exposure data. Dr. Burchiel
will work with the other two PI's, Dr. Parvez (Project 2, Columbia Univ) and Dr. Santella (Project 3, Columbia
Univ), to test the hypothesis that in vivo exposure of humans to cigarette smoke and arsenic produces
synergistic immunosuppression of T cell proliferation, T cell differentiation, and T cell/HPBMC cytokine
production. Project 1 relies upon Project 2 to measure cytokine production as well as to provide relevant health
endpoints, including lung function and upper airway infection assessments. Project 1 also relies upon Project 3
to measure biomarkers of exposure in the urine from study subjects (1-hydroxypyrene, 1-OHP) and PAH-DNA
adducts in HPBMC. Dr. Parvez's Project 2 will assess several lung function endpoints of interest to the other
investigators as well as examine mechanisms of oxidative stress and cytokine production that may correlate
with inflammatory lung disease. Dr. Santella (Project 3) has had a longstanding interest in PAH-DNA adducts
in HPBMC and benefits from this study by assisting in testing the hypothesis that high arsenic exposure
potentiates PAH adduct formation, which might be a useful biomarker of co-exposures. Project 2 performs the
recruitment for the study, and the overall coordination of sample collection, record keeping and data collection,
and analysis which is overseen by an Administrative Core. In summary, this ViCTER program is highly
integrated, benefits all investigators, and will add substantial new knowledge to immunologic and pulmonary
health effects of combined cigarette smoke (surrogate for PAHs) and arsenic exposures, which present a huge
public health burden.
这个ViCTER应用程序补充了来自PI的RO1,该RO1旨在理解
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott W Burchiel其他文献
Scott W Burchiel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott W Burchiel', 18)}}的其他基金
Synergistic Immunosuppression by PAHs and Arsenite
PAH 和亚砷酸盐的协同免疫抑制
- 批准号:
8301069 - 财政年份:2012
- 资助金额:
$ 40.51万 - 项目类别:
Synergistic Immunosuppression by PAHs and Arsenite
PAH 和亚砷酸盐的协同免疫抑制
- 批准号:
8619625 - 财政年份:2012
- 资助金额:
$ 40.51万 - 项目类别:
Synergistic Immunosuppression by PAHs and Arsenite
PAH 和亚砷酸盐的协同免疫抑制
- 批准号:
8470646 - 财政年份:2012
- 资助金额:
$ 40.51万 - 项目类别:
EFFECTS OF IMMUNOTOXIC XENOBIOTICS ON HUMAN PERIPHERAL BLOOD CELLS IN VITRO
免疫毒性异生素对人外周血细胞的体外影响
- 批准号:
7205260 - 财政年份:2004
- 资助金额:
$ 40.51万 - 项目类别:
EFFECTS OF IMMUNOTOXIC XENOBIOTICS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
免疫毒性异生素对人外周血淋巴细胞的影响
- 批准号:
6568261 - 财政年份:2001
- 资助金额:
$ 40.51万 - 项目类别:
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 40.51万 - 项目类别:
Long-term exposure to arsenic, and the co-occurrence of uranium, in public and private drinking water: associations with cardiovascular and chronic kidney diseases in the California Teachers Study
公共和私人饮用水中长期接触砷以及同时存在铀:加州教师研究中与心血管和慢性肾脏疾病的关联
- 批准号:
10677410 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Programming of Epigenetic Clocks and Biomarkers from Early-life Arsenic Exposure
生命早期砷暴露的表观遗传时钟和生物标志物的编程
- 批准号:
10726009 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Plant-mediated arsenic-iron mineral transformations
植物介导的砷铁矿物转化
- 批准号:
IN230100031 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Discovery Indigenous
Migration of arsenic and uranium in environments during iron transformation
铁转化过程中环境中砷和铀的迁移
- 批准号:
23K13693 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of arsenic-contaminated groundwater purification technology to secure safe water resources in the Mekong Delta
开发砷污染地下水净化技术确保湄公河三角洲水资源安全
- 批准号:
23KK0199 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Field Instrument for Assessment of Arsenic Exposure
砷暴露评估现场仪器
- 批准号:
10484041 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Cadmium and Arsenic Effects on Pyrimidine Biosynthesis in Early Airway Development
镉和砷对早期气道发育中嘧啶生物合成的影响
- 批准号:
10568094 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Inter- and transgenerational effects of paternal arsenic exposure
父亲砷暴露的代际和跨代影响
- 批准号:
10565361 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Studies on the mechanisms of arsenic-induced vascular and muscular toxicity
砷引起的血管和肌肉毒性机制的研究
- 批准号:
23K06137 - 财政年份:2023
- 资助金额:
$ 40.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)